Drug Trial Radar · NCT00225615
A Phase 3, Multicenter, Open-Label Extension Study of Phenoptin in Subjects With PKU Who Have Elevated Phenylalanine Levels
Last checked: Nov 20, 2026Latest source record: Aug 20, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
100
Actual
Start
Nov 2005
Primary completion
Not stated
Study completion Jun 2006
Sponsor
- Lead sponsor
- BioMarin PharmaceuticalBioMarin (BMRN)
- Sponsor type
- Industry
- First posted
- Sep 26, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 8 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to evaluate the safety and tolerability of long-term Phenoptin treatment in subjects with PKU.
Conditions
- Phenylketonurias
Interventions
sapropterin dihydrochlorideDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary objective:
- - To evaluate the safety and tolerability of long-term Phenoptin treatment in subjects with PKU.
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Los Angeles, California
Site not named
Oakland, California
Site not named
Sacramento, California
Site not named
San Jose, California
Site not named
New Haven, Connecticut
Site not named
Atlanta, Georgia
Site not named
Chicago, Illinois
Site not named
Minneapolis, Minnesota
Site not named
St Louis, Missouri
Site not named
New York, New York
Site not named
Portland, Oregon
Site not named
Dallas, Texas
Site not named
Salt Lake City, Utah
Site not named
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.